The widespread use of anti-VEGF agents to treat exudative age-related macular degeneration effectively reduces the burden of blindness and vision loss caused by it, whereas the management of diabetic retinopathy requires disproportionate resources, including the availability of ophthalmologists who are trained in laser and surgery (11). The gene discussed is VEGFA; the disease is age-related macular degeneration.